stockrowWest Pharmaceutical Services, Inc.
WST Healthcare Medical Instruments & Supplies
West Pharmaceutical Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 billion, up 6.25% from fiscal 2024.
- Revenue
- +8.69%
- EPS
- +56.7%
- Free cash flow
- +12.3%
- Total debt
- +0.10%
Quarter to September 2026, against a year earlier
Follow WST
Alert me
West Pharmaceutical Services, Inc. (WST) Net income
West Pharmaceutical Services, Inc.'s net income for fiscal 2025 was $493.7M, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $638.9M. Over the past ten years it has ranged from $95.6M (fiscal 2015) to $661.8M (fiscal 2021); the current reading is higher than 73% of that period. West Pharmaceutical Services, Inc. ranks 6th of 51 Medical Instruments & Supplies companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $493.7M | 0.20% |
| FY2024 | $492.7M | (16.97%) |
| FY2023 | $593.4M | 1.28% |
| FY2022 | $585.9M | (11.47%) |
| FY2021 | $661.8M | 91.16% |
| FY2020 | $346.2M | 43.24% |
| FY2019 | $241.7M | 16.82% |
| FY2018 | $206.9M | 37.29% |
| FY2017 | $150.7M | 4.94% |
| FY2016 | $143.6M | 50.21% |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $214.0M | 38.96% |
| Jun 2026 | $154.0M | 10.95% |
| Mar 2026 | $138.8M | 5.07% |
| Dec 2025 | $132.1M | (5.64%) |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| MDLN Medline Inc. compare | $1.9B |
| RMD ResMed Inc. compare | $1.6B |
| BDX Becton, Dickinson and Company compare | $942.0M |
| ALC Alcon compare | $643.0M |
| WST West Pharmaceutical Services, Inc. | $638.9M |
| COO The Cooper Companies, Inc. compare | $570.3M |
| ALGN Align Technology, Inc. compare | $413.6M |
| SOLV Solventum Corporation compare | $156.0M |
| BAX Baxter International Inc. compare | −$723.0M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on WST
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement